StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
DMACDiaMedica Therapeutics Inc.
stockpulse.co.kr
Nasdaq
$8.72▲ 0.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $469.9MShares out 53.9M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

4
  • 8.12After-hours26.08.13 05:23
    4Ownership#●●●#●●●

    DiaMedica Therapeutics Inc.

    Insider Pauls Dietrich John of DiaMedica Therapeutics Inc. reported a change in beneficial ownership of company securities via SEC Form 4, dated August 10, 2026. This filing formalizes the adjustment in the executive's stock holdings, and investors should review the details of this insider transaction.…more

    $8.72+0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.11Pre-market26.08.11 21:45
    S-8Offering

    DiaMedica Therapeutics Inc.

    DiaMedica Therapeutics는 2019년 옴니버스 인센티브 플랜에 따라 350만 주의 보통주를 추가로 발행하기 위해 S-8 등록 신고서를 제출했습니다. 해당 주식 발행은 2026년 3월 16일 이사회 승인과 5월 20일 주주총회 의결을 거쳐 확정된 사항입니다.…more

    $8.72+0.17%vs prev close
    View filingShare
  • 8.10After-hours26.08.11 05:37
    10-QEarnings

    DiaMedica Therapeutics Inc.

    다이아메디카 테라퓨틱스는 2026년 2분기 실적 보고를 통해 DM199의 임상 시험 진행 상황과 운영 현황을 공시했습니다. 현재 회사는 급성 허혈성 뇌졸중(AIS) 치료제인 DM199의 ReMEDy2 임상 시험을 진행 중이며, 임상 사이트 활성화 및 등록 속도 개선을 위해 내부 임상 팀을 확대하고 프로토콜을 변경하는 등 대응 조치를 취하고 있습니다.…more

    $8.72+0.17%vs prev close
    View filingShare

3 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 3d agoPre-market26.10.22 21:03
    #●●●#●●●

    DiaMedica Therapeutics Enrolls 200th Patient In ReMEDy2 Phase 2/3 Trial…more

    DiaMedica Therapeutics has successfully enrolled its 200th patient in the Phase 2/3 clinical trial for its acute ischemic stroke treatment. An independent data monitoring board will conduct an interim analysis, with results expected in the first quarter of 2027.…more

    $8.72+0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.30Pre-market26.09.30 21:39

    ●●●●●●●● ●●●●● ●●●●●●

    DiaMedica announced it will present interim data from the first six patients in its Phase 2 trial for DM199, a treatment for fetal growth restriction, on October 23. This data release will provide early insights into the drug's efficacy and safety profile.…more

    $8.72+0.17%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →